Coeptis Therapeutics Holdings, Inc. (ZSQR) IPO - S-1 Filing, Stock & Insider Activity
Coeptis Therapeutics Holdings, Inc. IPO - Status & S-1 Filing
- Ticker: ZSQR
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2026-06-09
- Exchange: NASDAQ
- Expected price range: $12.00–$296.80
- Shares offered: 41,584,562
- SEC CIK: 0001759186 · View the S-1 on SEC EDGAR →
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Coeptis Therapeutics Holdings, Inc. (ZSQR) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-08. 10 Form 8-K material event filings were reported by ZSQR in the last 90 days. InsiderAlpha tracks every ZSQR SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Coeptis Therapeutics Holdings, Inc. (ZSQR)
Coeptis Therapeutics Holdings, Inc. trades under the ticker ZSQR. InsiderAlpha tracks 18 primary SEC Form 4 filings from 16 reporting insiders for ZSQR since 2026, sourced directly from SEC EDGAR.
| SEC CIK | 0001759186 |
|---|
90-Day SEC Filing Activity
| Form 4 filings (90d) | 2 |
|---|---|
| Form 8-K filings (90d) | 10 |
| Latest Form 4 filing | 2026-06-08 |
Recent ZSQR Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| BSG Series CM, LLC | 10% Owner | J - Other acquisition / disposition | 41.52M | $0.00 | - | SEC | |
| Michelle Ellen Burke | Co-Chief Executive Officer | A - Grant or award | 16.4K | $0.00 | - | SEC | |
| Philippe Deschamps | Director | M - Option exercise | 5.7K | $10.56 | $60K | SEC | |
| Philippe Deschamps | Director | A - Grant or award | 3.2K | $0.00 | - | SEC | |
| Chris Calise | Director | M - Option exercise | 5.7K | $10.56 | $60K | SEC | |
| Chris Calise | Director | A - Grant or award | 3.2K | $0.00 | - | SEC | |
| David Mehalick | CEO and President | M - Option exercise | 148.9K | $7.05 | $1.05M | SEC | |
| David Mehalick | CEO and President | A - Grant or award | 51.2K | $0.00 | - | SEC | |
| Christopher P. Cochran | Director | M - Option exercise | 5.7K | $10.56 | $60K | SEC | |
| Christopher P. Cochran | Director | A - Grant or award | 3.2K | $0.00 | - | SEC | |
| Brian Cogley | Chief Financial Officer | M - Option exercise | 10.0K | $10.56 | $106K | SEC | |
| Daniel Alexander Yerace | VP Operations | A - Grant or award | 20.0K | $0.00 | - | SEC | |
| Gene Salkind | Director | M - Option exercise | 5.7K | $10.56 | $60K | SEC | |
| Gene Salkind | Director | A - Grant or award | 3.2K | $0.00 | - | SEC | |
| Tara Desilva | Director | M - Option exercise | 5.7K | $10.56 | $60K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Coeptis Therapeutics Holdings, Inc. (ZSQR). Updated in real time as new filings are submitted to the SEC.
Most-Active ZSQR Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Christopher Ryan Schadel | 1 | - |
| BSG Series CM, LLC | 1 | - |
Recent ZSQR Form 8-K Material Events
- - Item 1.02, 7.01, 9.01 [SEC]
- - Item 1.01, 9.01 [SEC]
- - Item 1.01, 9.01 [SEC]
- - Item 5.02, 7.01, 9.01 [SEC]
- - Item 7.01, 8.01, 9.01 [SEC]
Recent Insider Filings
- - Christopher Ryan Schadel (Chief Marketing Officer)
- - BSG Series CM, LLC (10% Owner)
- - Adam Craig Sohn (Director)
- - Christopher Ryan Schadel (Chief Marketing Officer)
- - David Elias Halabu (Co-Chief Executive Officer)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ZSQR insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
ZSQR Insider Trading - FAQ
- What is the latest insider trade for ZSQR?
- Coeptis Therapeutics Holdings, Inc. (ZSQR) had 2 insider filings in the last 90 days, with the most recent on 2026-06-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying ZSQR stock?
- 0 insider purchases of ZSQR were filed in the last 90 days.
- How many insiders are selling ZSQR stock?
- 0 insider sales of ZSQR were filed in the last 90 days.
- Where can I see ZSQR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks ZSQR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $AAC Ares Acquisition Corp III
- $AACIU Armada Acquisition Corp. III
- $AACOU Abony Acquisition Corp. I
- $AACPU Apogee Acquisition Corp
- $AADX Applied Aerospace & Defense, Inc.
- $AAQL Antiaging Quantum Living Inc.
- $AAS Antharas Inc
- $AAT American Assets Trust, Inc.
- $AAVE Grayscale Aave Trust
- $ACAAU Averin Capital Acquisition Corp.
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live ZSQR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.